ZATTARIN, EMMA
 Distribuzione geografica
Continente #
EU - Europa 877
NA - Nord America 189
AS - Asia 170
AF - Africa 2
OC - Oceania 1
Totale 1.239
Nazione #
DE - Germania 700
US - Stati Uniti d'America 188
IT - Italia 64
SG - Singapore 56
CN - Cina 52
SE - Svezia 44
IN - India 27
IE - Irlanda 18
GB - Regno Unito 14
ID - Indonesia 12
RU - Federazione Russa 11
FR - Francia 8
VN - Vietnam 8
FI - Finlandia 6
HK - Hong Kong 6
JP - Giappone 6
CH - Svizzera 3
BE - Belgio 2
CZ - Repubblica Ceca 2
EG - Egitto 2
KR - Corea 2
NL - Olanda 2
RO - Romania 2
AU - Australia 1
CA - Canada 1
DK - Danimarca 1
PH - Filippine 1
Totale 1.239
Città #
Frankfurt am Main 687
Chandler 74
Singapore 43
Dublin 18
Milan 15
Ashburn 14
Bengaluru 11
Hyderabad 10
Princeton 10
Beijing 9
Dong Ket 8
Phoenix 8
Southend 8
Helsinki 6
Hong Kong 6
Jakarta 6
Rho 6
Santa Clara 5
Wilmington 5
Eitensheim 4
Shanghai 4
Voghera 4
London 3
Medford 3
Perugia 3
Rome 3
Zurich 3
Berlin 2
Bernareggio 2
Brno 2
Brussels 2
Bucharest 2
Cairo 2
Cambridge 2
Casorate Primo 2
Gioia del Colle 2
Manchester 2
Menlo Park 2
Menteng 2
Monza 2
New York 2
Upper Marlboro 2
Altamura 1
Ann Arbor 1
Buffalo 1
Chongqing 1
Cologne 1
De Kwakel 1
Des Moines 1
Drexel Hill 1
Florence 1
Gangnam-gu 1
Groningen 1
Grünwald 1
Holbaek 1
Kilburn 1
Kure 1
Los Angeles 1
Montreal 1
Nanjing 1
Naples 1
Nuremberg 1
Orta di Atella 1
Padova 1
Pune 1
San Diego 1
Santa Maria 1
Seattle 1
Seoul 1
Sydney 1
Tokyo 1
Urbino 1
Zibo 1
Totale 1.037
Nome #
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy 116
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 107
Evaluation of drug-drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-kinase inhibitors 100
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin 99
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 94
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients 94
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab 91
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 88
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study 87
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report 85
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer 83
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications 76
Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic 74
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy 73
null 3
Abstract HER2-02: HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy 1
Totale 1.271
Categoria #
all - tutte 3.415
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.415


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 1 2 9
2021/202265 0 3 2 1 4 2 1 8 2 1 16 25
2022/2023247 23 25 18 18 24 45 5 23 32 4 29 1
2023/2024649 11 10 14 13 44 35 111 82 40 88 104 97
2024/2025298 84 99 92 23 0 0 0 0 0 0 0 0
Totale 1.271